Combination treatment for recurrent brain tumor
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of two medicines—hydroxychloroquine and temozolomide—for adults whose glioblastoma (a brain tumor) has come back after standard treatment. The hope is that this combination can slow or shrink the tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years old or older.
- You must have had surgery for glioblastoma and already received a standard treatment called temozolomide (chemo) plus radiation.
- An MRI must show that your brain tumor has come back (recurred).
- You should not have serious heart disease.
- Your recurrent tumor should not be growing so fast that it needs to be removed with surgery.
- This trial is not for a specific type called H3K27M midline glioblastoma.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests the safety and early effectiveness of BEY1107 combined with temozolomide in adults whose glioblastoma has come back or kept growing after standard treatment. If you qualify, you may be able to receive this combination while the researchers closely monitor side effects and tumor response.
This trial tests a combination of two drugs, bortezomib and temozolomide, for people whose brain tumor (glioblastoma) has returned after initial treatment. It's designed for tumors that don't respond well to standard treatments, and the goal is to see if this combination can help control the cancer.
This trial tests a combination of two drugs (temozolomide and dexbrompheniramine) to treat high-grade gliomas that have come back after standard treatment. The goal is to see if this combination can help control the tumor or slow its growth.
This trial tests a combination of two drugs—ivoximab (a new immunotherapy) and temozolomide (chemotherapy)—to treat gliomas (brain tumors) that have come back or stopped responding to prior treatment. The goal is to see if this combination is safe and effective.
This trial tests a combination of three drugs—trimipramine (an antidepressant), atezolizumab (an immunotherapy), and bevacizumab (a targeted therapy)—in people whose glioblastoma has come back after initial treatment. The goal is to see if this mix can help shrink the tumor or slow its growth.
This Phase 2 study tests whether adding recombinant human endostatin to temozolomide and irinotecan can slow or control recurrent gliomas (brain tumors) after prior standard treatment. It may help by targeting tumor blood vessel growth while also using chemotherapy to attack cancer cells.
Hear when a new Glioblastoma Multiforme trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.